Prognostic value of cyclin B1 protein expression in colorectal cancer

Am J Clin Pathol. 2004 Oct;122(4):511-6. doi: 10.1309/54H4-Q88A-1UBB-WPTE.


We used immunohistochemical analysis to study the expression and prognostic impact of cyclin B1, a key molecule for G2-M phase transition during the cell cycle, in a series of 342 curatively resected colorectal carcinomas. In 269 tumors (78.7%), high expression of cyclin B1 in more than 10% of tumor cells was observed, but there was no association between cyclin B1 expression and histopathologic tumor features. Univariate analysis revealed no impact on disease-free and overall survival. Multivariate analysis revealed pT and pN categories, extramural blood vessel invasion, and low-grade tumor cell differentiation as independent prognostic predictors for overall survival, and pT and pN categories and tumor site for disease-free survival. According to our results, high expression of cyclin B1 is a frequent and early event in colorectal carcinomas. However, cyclin B1 expression is neither a predictor of prognosis in patients with colorectal cancer nor a suitable tool for identifying subgroups of patients at higher risk for disease recurrence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Colorectal Neoplasms / chemistry*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology
  • Cyclin B / analysis*
  • Cyclin B1
  • Disease-Free Survival
  • Female
  • G2 Phase
  • Humans
  • Immunohistochemistry
  • Intestinal Mucosa / chemistry
  • Male
  • Middle Aged
  • Mitosis
  • Prognosis


  • CCNB1 protein, human
  • Cyclin B
  • Cyclin B1